Acquisition costs of biologic agents exceed that of older anti-rheumatic therapies. Therefore, appropriate phar-macoeconomic assessment must take into consideration the costs of the therapies themselves, but also the costs of the disease, in terms of work disability and the interference with the ability to perform activities of daily living. Highly effective therapies may be shown to be cost-effective if they are able to prevent some of the cost to the individual and society of a worsening of rheumatic disease. Several recent studies have demonstrated the potential cost-effectiveness of anti-TNF-a agents in PsA (Bansback et al. 2004; Guh et al. 2005; Marra 2005).
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.